Covid-19: Decision on Zydus Cadila ZyCov-D approval expected soon, says Dr VK Paul
ZyCoV-D is an intradermal vaccine, which is applied using The PharmaJet needle-free system, Tropis, which can also lead to a significant reduction in any kind of side effects.
New Delhi: A decision on the approval of Zydus Cadila's COVID-19 vaccine Zydus Cov-D is expected soon, Dr VK Paul, Member (Health) of the NITI Aayog said on Friday, adding that the data and evaluation would determine the outcome.
"The Drugs Controller General of India (DCGI) has Zydus Cadila's application. It is undergoing a process of evaluation by the Subject Expert Committee. We are hoping to hear a swift and positive decision," Dr Paul told ANI.
The Ahmedabad-based pharmaceutical firm has requested emergency use approval for ZyCoV-D, a three-dose Covid shot which is the world's first Plasmid DNA vaccine.
"It will be a moment of pride as it is a unique technology. It will give a push to the country's vaccination program," Dr Paul said.
ZyCoV-D is an intradermal vaccine, which is applied using The PharmaJet needle-free system, Tropis, which can also lead to a significant reduction in any kind of side effects.
Zydus also claims that it is 66.6 per cent effective against symptomatic Covid cases and 100 per cent for moderate disease. No severe cases or deaths due to COVID-19 occurred in the vaccine arm after administration of the second dose of the vaccine.
A recent statement by the pharma company said, "The vaccine when approved will help not only adults but also adolescents in the 12 to 18 years age group."
The company is planning to manufacture 10 - 12 crore doses annually and 5 crore by the month of December.
Read also: Zydus Cadila COVID vaccine for children above 12 years expected by August: NTAGI chief
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.